Synaptotagmin VIII Inhibitors

Chemical inhibitors of Synaptotagmin VIII have various modes of action that impact the protein's role in synaptic vesicle fusion and neurotransmitter release. Tetanus toxin and botulinum toxin A specifically target components of the SNARE complex, a critical apparatus for synaptic vesicle fusion to which Synaptotagmin VIII is functionally linked. Tetanus toxin cleaves synaptobrevin, while botulinum toxin A cleaves SNAP-25, both of which are proteins essential for the SNARE complex's integrity and operation. By disrupting the formation of the SNARE complex, these toxins indirectly inhibit the functionality of Synaptotagmin VIII. Similarly, Clostridial toxins and Conus toxin undermine the SNARE complex's role, with the former cleaving VAMP and the latter blocking calcium channels that are essential for synaptic vesicle turnover, which indirectly affects Synaptotagmin VIII's ability to trigger vesicle fusion.

Other inhibitors such as α-latrotoxin cause a massive influx of calcium into neurons, leading to a depletion of vesicular substrates and, thus, indirectly affecting Synaptotagmin VIII by exhausting its role in mediating exocytosis. Calcium channel inhibitors like ω-Agatoxin IVA, SNX-482, ω-Conotoxin GVIA, and ω-Conotoxin MVIIC interfere with calcium entry into the neuron, a critical trigger for Synaptotagmin VIII's function in vesicle fusion. Bafilomycin A1 disrupts proton pump function, which is necessary for neurotransmitter loading into vesicles, indirectly affecting Synaptotagmin VIII's role in neurotransmitter release. In contrast, ShK toxin prolongs action potentials by blocking potassium channels, which can disrupt calcium channel function and thus Synaptotagmin VIII's action in neurotransmission. ML-SI3 targets a similar protein, Synaptotagmin I, and by doing so, it may influence the vesicle fusion process in which Synaptotagmin VIII is involved, albeit indirectly.